A Multicenter Study on Observed Discrepancies Between Vendor-Stated and PET-Measured 90 Y Activities for Both Glass and Resin Microsphere Devices

[摘要] After years of development and many published studies, prostate-specific membrane antigen–targeted radioligand therapy recentlyreached a critical milestone on March 23, 2022, with approval of177Lu-PSMA-617 by the U.S. Food and Drug Administration (1).This landmark success heralds a new era of large-scale theranosticsfor nuclear medicine. This editorial provides the first-hand perspective on the origins of the phase III VISION trial and, specifically, thecreation of the imaging criteria for selection of patients for PSMAtargeted therapy.

[学科分类] 医学（综合）